Combinations and modes of administration of therapeutic agents and combination therapy
AssigneeAbraxis BioScience, LLC
InventorsNeil P. Desai, Patrick Soon-Shiong
Life of this patent
Estimating the term…
Abstract
The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.
Claims42
A method for treating non-small cell lung cancer (NSCLC) in a human individual comprising intravenously administering to the individual:
- a) an effective amount of a composition comprising nanoparticles comprising paclitaxel coated with albumin, and b) an effective amount of carboplatin, wherein the nanoparticle composition is free of cremophor.
The method of clam 2, wherein the nanoparticle composition is administered on a weekly schedule and the dosage of paclitaxel in the nanoparticle composition is in the range of 50-250 mg/m2.
A method for treating non-small cell lung cancer (NSCLC) in a human individual comprising intravenously administering to the individual:
- a) an effective amount of a composition comprising nanoparticles comprising paclitaxel coated with human serum albumin, wherein the nanoparticle composition is free of cremophor, wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm, wherein the nanoparticle composition is administered on a weekly schedule and the dosage of paclitaxel in the nanoparticle composition is 100 mg/m2, and b) an effective amount of carboplatin, wherein the carboplatin is administered once every three weeks and at the dose of AUC=6.
Dependencies are inferred from the claim text.